about
Transport and pharmacological properties of nine different human Na, K-ATPase isozymesRegional expression of sodium pump subunits isoforms and Na+-Ca++ exchanger in the human heart26-10 Fab-digoxin complex: affinity and specificity due to surface complementarityDiscovery of novel antifungal (1,3)-beta-D-glucan synthase inhibitorsAssociation of PI3K-Akt signaling pathway with digitalis-induced hypertrophy of cardiac myocytesMedical management of congestive heart failure.Mutation of a cysteine in the first transmembrane segment of Na,K-ATPase alpha subunit confers ouabain resistance.Effect of inhibition of Na+/K(+)-adenosine triphosphatase on vascular action of vasopressin.Digoxin associates with mortality in ESRD.Mechanistic distinction between activation and inhibition of (Na(+)+K(+))-ATPase-mediated Ca2+ influx in cardiomyocytes.Inhibitory effects of digoxin and digitoxin on corticosterone production in rat zona fasciculata-reticularis cells.Human breast tumor cells are more resistant to cardiac glycoside toxicity than non-tumorigenic breast cells.Therapeutic potential of c-Myc inhibition in the treatment of hypertrophic cardiomyopathy.Acid-base and electrolyte abnormalities observed in patients receiving cardiovascular drugs.Adverse drug effects: Part II.Excavatolide B Modulates the Electrophysiological Characteristics and Calcium Homeostasis of Atrial Myocytes.Ouabain prevents pathological cardiac hypertrophy and heart failure through activation of phosphoinositide 3-kinase α in mouse.Positive inotropes in heart failure: a review articleActivation of (Na+ + K+)-ATPase modulates cardiac L-type Ca2+ channel functionDifferent roles of the cardiac Na+/Ca2+-exchanger in ouabain-induced inotropy, cell signaling, and hypertrophy.Drug therapy considerations in arrhythmias in childrenAtrial fibrillation: mechanisms, therapeutics, and future directions.Recent developments in the treatment of congestive heart failure.Improving medication prescribing and utilization in the nursing home.Na/Ca exchange and contraction of the heart.Extracorporeal treatment for digoxin poisoning: systematic review and recommendations from the EXTRIP Workgroup.Design, synthesis, and negative inotropic evaluation of 4-phenyl-1H-1,2,4-triazol-5(4H)-one derivatives containing triazole or piperazine moieties.An evidence-based review of recent advances in therapy for heart failure with reduced ejection fraction (HFrEF).Of channels and pumps: different ways to boost the aldosterone?Cardiac glycosides exert anticancer effects by inducing immunogenic cell death.Incidence of digoxin toxicity in outpatients.Drug therapy of the fetus.Changing physician behavior in ordering digoxin assays.Influence of cloned voltage-gated K+ channel expression on alanine transport, Rb+ uptake, and cell volume.Effects of digoxin on cardiac iron content in rat model of iron overload.Influence of physical exercise on serum digoxin concentration and heart rate in patients with atrial fibrillationGood outcome after digoxin toxicity despite very high serum potassium level.Clarithromycin induced digoxin toxicity.Magnesium sulfate in the treatment of ventricular arrhythmias due to digoxin toxicity.The in vitro effect of exogenous digoxin on normal human spermatozoa progressive motility.
P2860
Q22011056-FD5BAECD-513F-4DFA-8BAA-0694F3B661D0Q24561959-C45B1215-4E1A-4FF7-AC6F-88AB7993C7EAQ27731455-4F436A7D-F1FE-408D-B3AE-C0D50CB74132Q28343863-9B4FDB1C-1B74-4BF6-82A9-152484721D20Q28566041-7AEED9CB-309A-4F2B-B60C-4BC3197F063DQ33558612-0D06318A-59F5-481C-B172-87AD6BFF97C9Q33937699-D0A8811E-3E40-4D23-9E51-7B05DA2F2642Q34261863-9446228D-2AF3-49BC-9C9C-5450DF3ADDE6Q34455390-CB79488A-3DBD-4C1C-A563-15CF945477DCQ34735710-96058883-826E-45AB-AC26-51AE45731267Q35047465-4CB10112-1124-4137-8D68-8A8A215C6641Q35071149-CE35FDA3-4BD1-4F38-8AD5-DF9CA0E9AD8DQ35165627-85F45DC3-30C4-4348-97F5-73324A49B4BCQ35636701-B2DA315B-D767-41FD-8EFB-BF690FA4D802Q36069466-9E4A280A-0414-4729-B9F3-518760458842Q36260790-143C96C0-6496-4AE5-B250-767DE9AC804CQ36298545-EA347322-FBA8-4417-80EA-E178EC3E270EQ36982705-070DA0B8-1C32-43B2-A74E-7E61BEAF5C8CQ37135681-F958ACB5-343A-4FAD-A0A8-E7257A15A891Q37175543-AEFF0814-66C2-4E6A-9E75-25AB0B9B7AC4Q37235054-0A515A15-3570-4A99-A343-2A1A18AF663DQ37590158-7BC7BE43-30E4-4A6E-BB8B-EA64E797C4AEQ37615740-D01D12D5-076D-408A-B34F-DD9C26D5C0C4Q37919728-1E7D78E6-72D0-4A91-8FA2-55D48562F454Q38114737-DFA4A8ED-3276-45F8-A231-114C6858E432Q38706177-319388AF-E168-472F-9C9D-DB6B6D0BC353Q38755329-EC3FA1F2-9D0A-4B90-93C7-01A567C8D229Q38973132-9FBCE178-2E94-4726-BE2F-018E8007A20FQ39013180-7F7D1331-FF68-4E63-8A80-046A614CF5E9Q39311553-861E746B-6E13-4F99-BE3D-4880B9BE646AQ39383560-3E696AB0-EE17-47A8-AE54-B43D32A250B8Q40774785-2D9234DD-68F7-4566-A409-EAD17DFC2242Q41063484-82200E3D-4083-403E-A485-6D59F4B49112Q41516857-1C7B866A-2BF3-43A5-B768-A5DD995E1A3FQ41856386-0C6930F1-DB91-48D5-90C9-5255540A07F0Q41989836-9DE9CAC8-9DC5-46DE-BE7F-8E6318296316Q42184656-107F0079-B0B1-45DC-B789-2923B66B4475Q42223018-EBD2A478-0ADA-4890-AA42-2C21508057E1Q42280503-AC4618A1-8BB0-4662-813D-943E1E0F6AD1Q43224283-50ABD11F-8D07-4FBC-BF47-D56E8E0B2F19
P2860
description
1988 nî lūn-bûn
@nan
1988年の論文
@ja
1988年論文
@yue
1988年論文
@zh-hant
1988年論文
@zh-hk
1988年論文
@zh-mo
1988年論文
@zh-tw
1988年论文
@wuu
1988年论文
@zh
1988年论文
@zh-cn
name
Digitalis. Mechanisms of action and clinical use.
@en
Digitalis. Mechanisms of action and clinical use.
@nl
type
label
Digitalis. Mechanisms of action and clinical use.
@en
Digitalis. Mechanisms of action and clinical use.
@nl
prefLabel
Digitalis. Mechanisms of action and clinical use.
@en
Digitalis. Mechanisms of action and clinical use.
@nl
P1476
Digitalis. Mechanisms of action and clinical use.
@en
P2093
P304
P356
10.1056/NEJM198802113180606
P407
P577
1988-02-01T00:00:00Z